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This special issue is fully dedicated to the topic of azoospermia and contains the seminal work of renowned
scientists and clinicians from seven countries on three continents. In seventeen chapters, a comprehensive
review of the epidemiology, genetics, physiopathology, diagnosis, and management of azoospermia addresses
our current knowledge on the topic. The clinical results of assisted reproductive techniques applied to this
category of male infertility and the health of offspring originating from such fathers are critically analyzed. In
addition, the challenges and the future biotechnological perspectives for the treatment of azoospermic males
seeking fertility are discussed.
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Two major breakthroughs revolutionized the field of male
infertility in the last three decades. The first was the
development of intracytoplasmic sperm injection (ICSI) for
the treatment of male factor infertility, and the second was
application of ICSI to azoospermic males, with the demon-
stration that spermatozoa derived from either the epididy-
mis or the testis were capable of normal fertilization and
pregnancy. Azoospermia, defined as the complete absence
of spermatozoa in the ejaculate, invariably results in
infertility but does not necessarily imply sterility. In fact,
azoospermia has been recognized as one of the most
intriguing topics in male infertility. Due to the true nature
of research involving the classical disciplines of physiology,
biochemistry and molecular biology, a rapid rise in the
volume of scientific knowledge regarding azoospermia has
been obtained. Invariably, this has led to a better under-
standing of the multi-faceted aspects of azoospermia.
However, there is still relatively little data within the
literature supporting common clinical practices. The repro-
ductive potential of azoospermic males with different
etiologies is unclear; furthermore, the association of an
increased risk of birth defects and potential iatrogenic
transmission of genetic abnormalities with ICSI using sperm
retrieved from these patients is still under debate.
The scope of azoospermia related-infertility now covers a
wide spectrum, including genetic studies, hormonal control,
microsurgical and medical therapy, assisted reproduction
techniques, and innovative stem cell research that aims to
create artificial gametes. In this special issue of Clinics, we
invited leading, internationally recognized scientists and
clinicians from the various sub-specialties to compile a
collection of high-quality and comprehensive reviews
highlighting the most current advances and contentious
issues in azoospermia. Our aim is to provide readers with a
thoughtful and wide-ranging review of the epidemiology,
genetics, physiopathology, diagnosis, and management of
azoospermia. The text is the first of its type and represents
an invaluable tool for both basic scientists with an interest in
sperm biology and clinicians (urologists, gynecologists,
reproductive endocrinologists, and embryologists) working
in the field of infertility. The selection of topics demon-
strates the exciting breadth of this category of male
infertility and the opportunity that research in this area
holds for both understanding and improving the reproduc-
tive health of azoospermic males.
This Special Issue commences with provocative insights
into the genetic and epigenetic paternal contribution to the
human embryo (1). Dada and colleagues from New Delhi
present the current knowledge on the role of spermatozoa as
highly specialized cells with the purpose of not only
delivering competent paternal DNA to the oocyte but also
providing a robust epigenetic contribution to embryogen-
esis. The paternal epigenetic contribution to embryogenesis
requires that both the sperm DNA and the chromatin
structure as a whole contain layers of regulatory elements
that are sufficient to drive genes towards activation or
silencing upon delivery to the egg. Changes in the
epigenome are now known to affect gene expression, and
several genes participating in spermatogenesis have been
demonstrated to be epigenetically regulated.
The second article by Marcello Cocuzza and colleagues
from the University of Sa˜o Paulo is a comprehensive review
of the epidemiology and etiology of azoospermia.
According to these authors, azoospermia is identified in
approximately 1% of all men and 10% to 15% of infertile
males (2). With a population of approximately 3 billion
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people at reproductive age, a gross estimate indicates that
approximately 10 million men worldwide are azoospermic.
The authors explore several conditions that may lead to
azoospermia and didactically divide them into pre-testicu-
lar, post-testicular, and testicular causes. Despite the
advances in the diagnostic tools that identify men with
genetic-origin azoospermia, many men are still classified as
having idiopathic azoospermia because the specific etiolo-
gical factor remains unidentifiable. Therefore, determining
the etiology of azoospermia remains one of the main
challenges in this field.
Drs. Gudeloglu and Parekattil from the United States
follow the theme by highlighting the importance of the
clinical exam in the investigation of the azoospermic male.
The authors detailed review defines why and how the
clinical evaluation should be undertaken. They also discuss
the usefulness and limitations of testis biopsies and imaging
studies in the context of azoospermia and the importance of
genetic counseling before using the spermatozoa from men
with nonobstructive azoospermia (NOA) for assisted
reproductive techniques (3). Dr. Aziz provides a laboratory
perspective from the United Kingdom by cleverly defining
azoospermia as a descriptive term for ejaculates that lack
spermatozoa without implying a specific underlying cause
(4). The author stresses that proper techniques are needed to
reduce the amount of analytical error and enhance sperm
count precision when evaluating semen specimens. The
correct assessment of an initially azoospermic semen speci-
men should be followed by an examination of the pelleted
semen to exclude cryptozoospermia, which is defined by the
presence of a very small number of live sperm in a
centrifuged pellet. An accurate assessment of very low
sperm counts aims to avoid labeling severely oligozoosper-
mic men as azoospermic, which is particularly important in
the current era of assisted reproduction technology. Dr.
Azizs chapter provides insightful information on the
seminal plasma biomarkers that may aid in determining
the causes of azoospermia. Laboratory seminology is clearly
moving from the assessment of conventional semen profiles
into the assessment of sperm function. This strategy is likely
to aid in the understanding of the underlying pathophysiol-
ogy of male infertility, and noninvasive biomarkers may be
useful in discriminating NOA cases from obstructive
azoospermia (OA).
This Special Issue contains an authoritative article that
provide the current knowledge on the genetic aspects of
azoospermia and the testing available for clinical use. Dr.
Hamada and his co-authors from the Cleveland Clinic
provide an immense summary of results on the genetic
aspects of male infertility and implication of these results on
the diagnosis and treatment of azoospermic males (5).
Molecular biology genetic testing involving the Y-chromo-
some can now correctly identify azoospermic men mis-
diagnosed as having idiopathic infertility. Moreover, Y-
chromosome testing is of prognostic value for sperm
retrieval in NOA. The authors also present practical
recommendations for testing, and they discuss the possible
implications of using spermatozoa from men with genetic
abnormalities for assisted conception.
In the clinical setting, azoospermic patients are diagnosed
as having obstructive or nonobstructive azoospermia.
Obstructive azoospermia has been attributed to a mechanical
blockage that can occur anywhere along the reproductive
tract, including the vas deferens, epididymis, and ejaculatory
duct. OA is considered to be one of the most favorable
prognostic conditions for male infertility because sperma-
togenesis is not disrupted, unlike in NOA. Drs. Baker and
Sabanegh from the Cleveland Clinic discuss the current
indications, techniques and results of reconstructive
procedures in OA (6). These authors highlight
the refinements in microsurgery that have optimized the
success of reconstructive procedures; additionally, the
authors indicate that the use of optical magnification is
now the gold standard for vasal reconstruction. While the
results of reconstructive procedures are excellent follow-
ing vasectomies, other complex repairs may be required,
especially in other etiological categories of OA. Despite
being highly successful, microsurgical reconstruction may
not be indicated in all men with OA, such as in patients
with congenital bilateral absence of vas deferens (CBAVD)
and certain cases of post-infectious obstructions or failed
vasectomy reversals. In such cases, sperm retrieval can be
performed for use with ICSI.
Nonobstructive azoospermia, on the other hand, poses a
different challenge. From the management standpoint, men
with NOA are the most difficult to treat, and extensive
debate exists on the benefit of intervention for this category
of male infertility. Various conditions may cause NOA,
including genetic and congenital abnormalities, post-infec-
tious issues, exposure to gonadotoxins, medications, var-
icocele, trauma, endocrine disorders, and idiopathic causes.
This Special Issue contains three articles that critically
explore the role of medical and surgical therapy in
nonobstructive azoospermia.
Renato Fraietta and colleagues from the Federal
University of Sa˜o Paulo provide a timely review on
hypogonadotropic hypogonadism (HH), which is a failure
of spermatogenesis due to a lack of appropriate stimulation
by gonadotropins (7). This category of patients includes not
only congenital forms of HH but also a subset of men whose
spermatogenic potential has been suppressed by excess
androgens or steroids. These patients benefit from specific
hormonal therapy and often show remarkable recovery of
spermatogenic function with exogenously administered
gonadotropins or gonadotropin releasing hormone.
Unfortunately, not all men with NOA have HH. In fact,
the larger category of NOA consists of men with intrinsic
testicular impairment in which empirical medical therapy
shows little benefit, as noted by Dr. Rajeev Kumar from the
All India Institute of Medical Sciences in New Delhi (8).
However, due to the developments in ART, a renewed
interest in the role of interventions in this subset of NOA
patients has developed. The author expertly discusses the
role of medical therapy in these men to improve the
quantity and quality of sperm that can be eventually
retrieved from their ejaculates or from their testes for use
in ICSI. In this sense, gonadotropins, aromatase inhibitors
and non-steroidal antiestrogens show promise in achieving
this endpoint. Lastly, Dr. Kubilay Inci from Turkey provides
a critical appraisal on the role of varicocele repair for
men with NOA (9). His authoritative review discusses
the pathophysiology of varicocele-related infertility, and the
discussion is supported by his own experience on the
impact of varicocele repair in azoospermic patients. From
the limited published data, it has been suggested that
varicocele repair may not only allow small quantities of
sperm to appear in the ejaculate but also may enhance the
chances of retrieving sperm from the testis of these patients.
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Even a minimal restoration of sperm production facilitates
sperm injection procedures.
Currently, ART is the only option for most men with
azoospermia-related infertility to have their biological off-
spring. Success has been achievedwith ICSI in both obstructive
and nonobstructive azoospermia, and the use of non-ejaculated
sperm coupled with ICSI has become a worldwide established
procedure. Surgical methods have been developed to retrieve
spermatozoa from the epididymides and testes. After sperm
retrieval, ICSI is used rather than standard IVF because ICSI
has been shown to result in a significantly higher fertilization
rate. A section of this Special Issue comprised of seven articles
is fully dedicated to the use of assisted conception in
azoospermia-related infertility. The authors of these selected
titles have extensive publication records and more than a
decade of clinical and/or laboratory experience in the manage-
ment of azoospermic males using assisted conception. In the
first article of this section, the authors prepared a comprehen-
sive summary of the current methods for sperm retrieval and
critically analyzed the advantages and disadvantages of each
method (10). The authors note that the sperm retrieval (SR)
method of choice is often based on the type of azoospermia and
the attending surgeon’s preferences. However, SR should aim
to both minimize damage to the reproductive tract, thereby
preserving the chance of repeated retrieval attempts, and to
obtain an adequate number of good quality sperm that can be
immediately used for ICSI or alternatively cryopreserved for
future ICSI attempts. Following this theme, two articles from
Brazilian groups discuss the key elements for the success of
sperm retrieval in obstructive and nonobstructive azoospermia
(11,12). Dr. Miyaoka and colleagues summarize the current
knowledge on the impact of several factors on sperm injection
outcomes using surgically retrieved sperm frommenwith OA.
The authors conclude that SR in OA is highly successful and
that causes of obstruction and retrieval methods have little
impact on SR success rates. Moreover, current evidence
suggests that similar pregnancy outcomes are achieved by
ICSI in OA using either fresh or frozen-thawed epididymal or
testicular sperm (11). While a successful retrieval attempt is
obtained in virtually all cases of OA, Drs. Glina and Vieira
highlight the uncertainty of sperm acquisition in cases of NOA,
thus making it desirable to determine the prognostic factors.
The authors review several clinical and laboratory prognostic
markers, such as the etiology of NOA, paternal age, testicular
volume, serum levels of pituitary gonadotropins, genetic
testing results, method of collection, testicular histopathology
results and the impact of the laboratory tissue processing
method; the authors concluded that the only unfavorable
indicator for SR is the presence of microdeletions in the AZFa
and/or AZFb regions of the Y chromosome long arm (12).
Another key message from this review is that men with NOA
are no longer considered sterile, even with elevated follicle-
stimulating hormone levels and small testes, because modern
retrieval techniques can be used to collect testicular sperm and
produce a healthy biological offspring via assisted conception.
The laboratory management of surgically retrieved
gametes requires special attention because spermatozoa
collected from azoospermic men are often compromised in
quality and more fragile. Drs. Popal and Nagy from Atlanta
provide strategies for handling such gametes inside the
laboratory and discuss potential dangers (13). Adherence to
state of the art laboratory techniques and quality control are
recommended to avoid jeopardizing the fertilizing potential
of the sperm and chances of achieving a live birth. Several
techniques are described for optimizing the chances of
harvesting spermatozoa from epididymal fluid and testi-
cular tissue of azoospermic men. The concept of cryopre-
servation may also be used in association with sperm
retrieval procedures. Some centers prefer to retrieve and
intentionally cryopreserve sperm for future use. This
strategy offers the advantage of avoiding ovarian stimula-
tion when no sperm is obtained from testicular specimens. If
sperm is retrieved and frozen, it can be thawed at any time,
thereby avoiding the need to organize two operations (oocyte
and sperm retrieval) on the same day. Additionally,
cryopreservation may spare unused specimens that would
be discharged after ICSI, whichmay be useful if the treatment
cycle does not result in a pregnancy. Therefore, future ICSI
attempts could be conducted without repeated surgical
retrievals. In most cases of epididymal retrievals, motile
sperm will be available after thawing, and ICSI outcomes
using fresh motile or frozen-thawed epididymal sperm do
not seem to differ. Cryopreservation of testicular sperm is
also advisable, especially for men with NOA who often
require multiple ICSI attempts to conceive but may not have
an adequate number of sperm available for repeated retrieval
attempts. These important aspects are discussed by Dr.
Gangrade from Orlando, who also presents laboratory
protocols for the cryopreservation of epididymal and
testicular sperm and discusses the reproductive outcomes
of using frozen-thawed gametes for sperm injections (14).
The closing articles of the section dedicated to assisted
reproduction are authored by the guest editors and Drs.
Veerle and colleagues from the Centre of Reproductive
Medicine in Brussels, who pioneered the introduction of
ICSI and revolutionized the treatment of male infertility in
the 90s. In our article, we summarized the data that have
been generated on the reproductive potential of azoosper-
mic men undergoing assisted conception (15). We per-
formed a systematic review of the literature focusing on
studies that directly compared pregnancy outcomes after
sperm injections between couples whose male partner had
OA or NOA. We also analyzed a personal database (SCE) of
370 couples who underwent ICSI according to the above-
cited categories and compared the outcomes with a group of
465 non-azoospermic infertile males. In our series of 1,092
ICSI cycles performed in 835 male infertility patients, live
birth rates were lowest in the NOA group. Miscarriage,
ectopic pregnancy, and multiple pregnancy rates did not
differ between clinical pregnancies achieved using ejacu-
lated or non-ejaculated sperm from men with OA or NOA.
In our series of 427 babies born with ICSI using sperm from
non-azoospermic infertile fathers and azoospermic fathers
with OA and NOA, the short-term neonatal outcomes were
similar among groups, despite a tendency towards higher
preterm birth in both azoospermia categories and lower
gestational age for twins in OA. The overall perinatal death
and malformation rates were 2.8% and 1.6%, respectively,
and our results did not differ between deliveries that
resulted from ICSI using ejaculated or non-ejaculated sperm
from men with OA or NOA. In our review, we critically
compare our results with other publications. We note that
most published studies, including our data, suffer from
methodological shortcomings. For instance, these studies
were not designed to detect differences in live birth rates
and not powered to detect differences in less frequent
outcomes, such as malformations and other complications.
Moreover, no follow-up study has yet compared the long-term
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physical, neurological and developmental outcomes of chil-
dren born with ICSI using sperm from azoospermic men with
OA andNOA.We conclude that for now, the limited evidence
on pregnancy and postnatal outcomes of ICSI using surgically
derived sperm from azoospermic men is reassuring; however,
a call for continuous monitoring is of utmost importance to
support the recommendation of sperm retrieval and ICSI in
azoospermia-related male infertility. Following this theme, an
authoritative review by Dr. Veerle and co-authors provides an
analysis of the results of immature germ cells used for ICSI
(16). This strategy has been proposed in cases of NOA in
which no spermatozoa can be retrieved. After the initial
disappointing results, the in vitro culture of immature germ
cells to more mature stages has been proposed as an approach
to improve this poor outcome. More than a decade has passed
since the introduction of ICSI with elongating and round
spermatids; there is still a lot of uncertainty regarding the
safety of this treatment option. The authors outline the clinical
and scientific evidence for ICSI using immature germ cells and
in vitro matured germ cells and describe the physiopatholo-
gical mechanisms involved in fertilization. In addition, these
authors suggest that despite reports of deliveries of healthy
offspring, the method has very low efficiency; furthermore,
most IVF programs worldwide have stopped spermatid
injection. Several ethical and safety concerns related to the
potential transmission of genomically imprinted disorders
have been raised, leading to the ban of spermatid injection in
countries such as the United Kingdom.
Research toward the development of artificial gametes is
timely due to the prevalence of NOA and inability of
harvesting mature sperm from the testes in approximately
half of patients. In addition, the overall efficiency of
spermatid injection is disappointing, and the reproductive
potential after ICSI using testicular sperm retrieved from
azoospermic men with dysfunctional spermatogenesis is
only fair. A recent breakthrough report by Japanese
scientists at Kyoto University used stem cells from mouse
embryos to create primordial germ cells, which were then
able to differentiate in spermatozoa after testis transplanta-
tion in mice. This topic is the theme of the closing article of
this Special Issue, namely the challenges and perspectives of
biotechnology and stem cell research to treat the most
severe cases of azoospermia and potentially ‘cure’ male
sterility (17). This article is authored by the group led by Dr.
Franca from the Federal University of Minas Gerais, Brazil,
in collaboration with Dr. Schlatt from Munster, Germany.
Dr. Franca is a leading authority in this field, and his
provocative insights on cell biology call for a profound
reflection. In their article, Dr. Franc¸a’s group proposes that
men with incomplete spermatogenesis are collectively
classified as aspermatogenic to indicate a highly severe
testicular pathology with complete absence of spermatids
and spermatozoa. The authors explore the novel biotechno-
logical methods to rescue fertility while maintaining
biological fatherhood. Human haploid-like cells have
already been obtained from pluripotent stem cells of
somatic origin using the novel technique of in vitro sperm
derivation. Germ cell transplantation as a form of grafting is
a promising method that may restore the fertility of
prepubertal boys who previously received cancer treat-
ments. Haploidization is being investigated as an option to
create gametes based on biological cloning technology.
Although promising, these methodologies are experimental,
and the production of human gametes in the laboratory is a
highly complex process that has yet to be translated to
reproductive medicine.
This Special Issue of Clinics aims to be a landmark treatise
on azoospermia. Scientists and clinicians from seven
countries on three continents have contributed generously
to the current scientific knowledge involving human
azoospermia and its role in male reproductive health. We
recommend its contents not only to students and research-
ers in the biological, veterinary and medical sciences but
also to clinicians involved in the management of infertile
couples and urologists, andrologists, gynecologists, embry-
ologists and reproductive specialists interested in following
the exponential growth in the knowledge of azoospermia.
Due to the multidisciplinary nature of this category of male
infertility, unsolved problems present themselves, and the
opportunities for advancement continue to expand. We
hope that readers will appreciate this Special Issue of Clinics
and share our excitement in the study of azoospermia.
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